GSK plc GLAXF OTC

GSK plc (GLAXF) generated $7.3B in operating cash flow for fiscal year 2025. After capital expenditures of $1.35B, free cash flow was $5.95B.

Free cash flow margin was 18.2% of revenue. Cash conversion ratio was 1.28x, indicating earnings are backed by cash.

The company returned $2.56B in dividends to shareholders during the period.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (90/100, Pass) — $5.95B (18.2% FCF margin) supports a durable competitive advantage
• INCOME (70/100) — Cash conversion ratio was 1.28x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 70/100 with 4/7 criteria passed.